Cadila Pharmaceuticals, one of the oldest and largest privately-held pharma companies in the country, has appointed Ashraf Allam as the Global Chief Operating Officer (COO).
Allam joined Cadila Pharmaceuticals on November 30. He will be based at Bhat corporate office and will report to Cadila’s Group Chairman and Managing Director Dr. Rajiv Modi.
An accomplished and well-regarded industry leader with more than three decades of experience, Allam was serving recently as the CEO at the Public Investment Fund prior to joining Cadila Pharmaceuticals.
He also serves as a board member for a number of US, European and regional Pharma, Biotech, Medical devices, Diagnostics, Self-medication and technology companies.
In addition, he is also serving as senior executive advisor for global private equity funds and family offices both in the USA, Europe and in the middle east.
Ashraf has a strong track record of holding senior positions at global multinational and privately-held companies such as Johnson & Johnson, Amgen, Eli Lilly, BMS and Mundipharma.
He brings a great mix of leadership, inspiration, operational experience, technical breadth, and passion for patients.
An energetic entrepreneur, global business leader, and strategic thinker, Allam has deep knowledge and extensive experience in building and managing businesses in the healthcare Industry.
His ability to drive growth of people and businesses, build brands, transform operations, scale-up capabilities, and successful corporate acquisitions and alliances have been the hallmark of his successful track record.
Allam has a Bachelor’s degree in Clinical Pharmaceuticals from Egypt and Post-Graduate Management Programmes from leading firms in the US and Europe.
“Cadila Pharmaceuticals is one of the oldest and most reputable well-established industry leaders both in India and globally.” Allam said.
“I look forward to work with Cadila’s executives and board of directors to drive a global powerhouse while upholding Cadila’s fundamental core principles; bringing both innovative and affordable medications to patients across the globe and always looking for innovative ways to transform the journey of patient care.” He added.
